Sharemaestro company-news research for Moderna, Inc. (M1RN34), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
SAO
Brazil
Measured evidence
Company news sentiment
M1RN34 news sentiment
Moderna, Inc.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone49Neutral is 50
Balanced news tone
51/100 evidence confidence
100% direct company focus
2 current stories across 1 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.
Latest source headline Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? finance.yahoo.com · 11 Aug 2026 00:18What supports the read
2 current stories are mapped specifically to M1RN34.
Cross-story agreement is 85/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
49/100
Weighted toneBalanced news tone
51/100
Evidence confidencebuilding confidence
100%/100
Company focus2 direct stories
85/100
Evidence agreement15/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth25
1.99 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness67
recency-weighted evidenceAgreement85
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings472 stories · 100%
Source mix
Where the evidence comes from
finance.yahoo.com472 stories · 100%
Recurring subjects
Subjects appearing most often
Fda Approval2Earnings2Patent Settlement1Net Income1Biotech1Balance Sheet1Artificial Intelligence1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#134Tone
finance.yahoo.comDirect company coverage
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for Moderna as it seeks to expand its commercial pipeline beyond COVID-19.Could Arbutus Biopharma Corporation (ABUS) Turn Its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech
Balance SheetBiotechEarningsFda ApprovalNet IncomePatent Settlement
- Published
- 11 Aug 2026 00:18
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#263Tone
finance.yahoo.comDirect company coverage
RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers
On this episode of Stock Movers:- RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week.- Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround.- Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom. View Comments
Artificial IntelligenceEarningsFda Approval
- Published
- 10 Aug 2026 15:16
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.